tbuckley/cabot-search huggingface dataset:
Dendritic Polyglycerol‐Conjugated Gold Nanostars for Metabolism Inhibition and Targeted Photothermal Therapy in Breast Cancer Stem Cells
Authors: Yuanwei Pan, Suqiong Zhou, Chuang Liu, Xuehua Ma, Jie Xing, Badri Parshad, Wenzhong Li, Aiguo Wu, Rainer Haag
Journal: Advanced Healthcare Materials (2022)

Breast cancer stem cells (CSCs) are believed to be responsible for tumor initiation, invasion, metastasis, and recurrence, which lead to treatment failure. Thus, developing effective CSC-targeted therapeutic strategies is crucial for enhancing therapeutic efficacy. In this work, GNSs-dPG-3BP, TPP, and HA nanocomposite particles are developed by simultaneously conjugating hexokinase 2 (HK2) inhibitor 3-bromopyruvate (3BP), mitochondrial targeting molecule triphenyl phosphonium (TPP), and CSCs targeting agent hyaluronic acid (HA) onto gold nanostars-dendritic polyglycerol (GNSs-dPG) nanoplatforms for efficient eradication of CSCs. The nanocomposite particles possess good biocompatibility and exhibit superior mitochondrial-bound HK2 binding ability via 3BP to inhibit metabolism, and further induce cellular apoptosis by releasing the cytochrome c. Therefore, it enhanced the therapeutic efficacy of CSCs-specific targeted photothermal therapy (PTT), and achieved a synergistic effect for the eradication of breast CSCs. After administration of the synergistic treatment, the self-renewal of breast CSCs and the stemness gene expression are suppressed, CSC-driven mammosphere formation is diminished, the in vivo tumor growth is effectively inhibited, and CSCs are eradicated. Altogether, GNSs-dPG-3BP, TPP, and HA nanocomposite particles have been developed, which will provide a novel strategy for precise and highly efficient targeted eradication of CSCs.
Canadian Medical Association Journal, Toronto
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Errors in Methods and Table
Journal: JAMA Network Open (2022)

Laura A. Wortinger, PhD; Claudia Barth, PhD; Stener Nerland, MSc; Kjetil Nordbø Jørgensen, PhD; Alexey A. Shadrin, PhD; Attila Szabo, PhD; Unn Kristin Haukvik, MD, PhD; Lars T. Westlye, PhD; Ole A. Andreassen, MD, PhD; Marianne Thoresen, MD, PhD; Ingrid Agartz, MD, PhD
Targeting circular RNA-MET for anti-angiogenesis treatment via inhibiting endothelial tip cell specialization
Authors: Mu-Di Yao, Qin Jiang, Yan Ma, Yan Zhu, Qiu-Yang Zhang, Ze-Hui Shi, Chen Zhao, Biao Yan
Journal: Molecular Therapy (2022)

Endothelial tip cell specialization plays an essential role in angiogenesis, which is tightly regulated by the complicated gene regulatory network. Circular RNA (circRNA) is a type of covalently closed non-coding RNA that regulates gene expression in eukaryotes. Here, we report that the levels of circMET expression are significantly upregulated in the retinas of mice with oxygen-induced retinopathy, choroidal neovascularization, and diabetic retinopathy. circMET silencing significantly reduces pathological angiogenesis and inhibits tip cell specialization in vivo. circMET silencing also decreases endothelial migration and sprouting in vitro. Mechanistically, circMET regulates endothelial sprouting and pathological angiogenesis by acting as a scaffold to enhance the interaction between IGF2BP2 and NRARP/ESM1. Clinically, circMET is significantly upregulated in the clinical samples of the patients of diabetic retinopathy. circMET silencing could reduce diabetic vitreous-induced endothelial sprouting and retinal angiogenesis in vivo. Collectively, these data identify a circRNA-mediated mechanism that coordinates tip cell specialization and pathological angiogenesis. circMET silencing is an exploitable therapeutic approach for the treatment of neovascular diseases. Endothelial tip cell specialization plays an essential role in angiogenesis, which is tightly regulated by the complicated gene regulatory network. Circular RNA (circRNA) is a type of covalently closed non-coding RNA that regulates gene expression in eukaryotes. Here, we report that the levels of circMET expression are significantly upregulated in the retinas of mice with oxygen-induced retinopathy, choroidal neovascularization, and diabetic retinopathy. circMET silencing significantly reduces pathological angiogenesis and inhibits tip cell specialization in vivo. circMET silencing also decreases endothelial migration and sprouting in vitro. Mechanistically, circMET regulates endothelial sprouting and pathological angiogenesis by acting as a scaffold to enhance the interaction between IGF2BP2 and NRARP/ESM1. Clinically, circMET is significantly upregulated in the clinical samples of the patients of diabetic retinopathy. circMET silencing could reduce diabetic vitreous-induced endothelial sprouting and retinal angiogenesis in vivo. Collectively, these data identify a circRNA-mediated mechanism that coordinates tip cell specialization and pathological angiogenesis. circMET silencing is an exploitable therapeutic approach for the treatment of neovascular diseases.
Лідія Яківна Мельниченко (До 75-річчя від дня народження)
Authors: . .
Journal: GASTROENTEROLOGY (2013)

8 серпня 2013 року доктору медичних наук, головному науковому співробітнику відділу захворювань печінки та підшлункової залози ДУ «Інститут гастроентерології НАМН України» Лідії Яківні Мельниченко виповнюється 75 років.
Editorial Comment on: Time, Symptom Burden, Androgen Deprivation, and Self-Assessed Quality of Life after Radical Prostatectomy or Watchful Waiting: The Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) Clinical Trial
Authors: Melina Gattellari, Jeanette E. Ward
Journal: European Urology (2008)
Risk Stratification for Arrhythmic Events in Patients With Asymptomatic Pre-Excitation: A Systematic Review for the 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia
Authors: Sana M. Al-Khatib, Aysha Arshad, Ethan M. Balk, Sandeep R. Das, Jonathan C. Hsu, José A. Joglar, Richard L. Page
Journal: Journal of the American College of Cardiology (2015)
HGCSG1902: Multicenter, prospective, observational study for patients with dysgeusia caused by chemotherapy for gastrointestinal cancer.
Authors: Ken Ito, Satoshi Yuki, Hiroshi Nakatsumi, Takayuki Ando, Kentaro Sawada, Masataka Yagisawa, Atsushi Ishiguro, Masayoshi Dazai, Ichiro Iwanaga, Kazuteru Hatanaka, Atsushi Sato, Ryusuke Matsumoto, Yoshiaki Shindo, Miki Tateyama, Tetsuhito Muranaka, Masaki Katagiri, Isao Yokota, Yuh Sakata, Naoya Sakamoto, Yoshito Komatsu
Journal: Journal of Clinical Oncology (2022)

649 Background: Dysgeusia is the one of important adverse events in patients treated with chemotherapy because it could reduce daily oral intake and worsen patient’s nutritional status. It is said that the lack of zinc is often observed in patients with chemotherapy because taste buds cells injured by chemotherapy require large amounts of zinc for their regeneration and cytotoxic agents have the possibility of working as a chelator for zinc. Some retrospective studies showed that zinc administration may improve dysgeusia in patients treated with chemotherapy, however, there is no prospective study. Therefore, we planned this study to clarify the effect of zinc therapy on dysgeusia in patients with gastrointestinal cancer. Methods: This was a multicenter, prospective observational study. From February 2020 to June 2021, patients with dysgeusia during chemotherapy for gastrointestinal cancer were enrolled from 17 institutes in Japan. The investigator selected one of the following treatment: no intervention (N), polaprezinc administration (P: contains 34.1mg of zinc par daily normal dose), or zinc acetate hydrate administration (Z: contains 50-100mg of zinc par daily normal dose). Serum zinc levels were measured at baseline, after 6 and 12 weeks, respectively. Dysgeusia was assessed by questionnaires according to four criteria, CTCAE v5.0, Subjective Total Taste Acuity (STTA), Visual Analogue Scale (VAS), and Chemotherapy-induced Taste Alteration Scale (CiTAS) at the time of enrollment and after 12 weeks. Results: A total of 180 patients, 60 in each group, were enrolled in the study. The mean serum zinc levels in each group at baseline were similar (67.3, 66.6, and 67.5μg/dl in N, P, Z group, respectively) and lower than lower limit of normal. The mean alterations of serum zinc level from baseline to after 12 weeks were -3.8, +14.3, and +46.6μg/dl in N, P, Z group, respectively. The STTA score was significantly improved in the P group compared to the N group at 12 weeks (p = 0.045), whereas it was not improved in the Z group (p = 0.945). The association between the alteration values of serum zinc level and improvement of dysgeusia was not observed. Conclusions: In this study, administration of polarezinc or zinc acetate hydrate increased serum zinc levels, but there was no significant correlation between the degree of serum zinc elevation and the improvement of dysgeusia. The STTA score was improved only in P group, thus our results suggest there are any factors for improvement of dysgeusia by polaprezinc administration other than serum zinc levels. Clinical trial information: UMIN000039653.
Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase Ⅱ clinical trial.
Authors: Junsheng Wang, Tao Wu, Suxia Luo, Ning Li, Yonggui Hong, Yanzhen Guo, Yufeng Cheng, Baosheng Li
Journal: Journal of Clinical Oncology (2022)

315 Background: Chemotherapy is the standard first-line therapy for advanced Esophageal Squamous Cell Carcinoma (ESCC). However, the poorly 5-year survival rate (4.8%) was unsatisfied. Anlotinib was an effective second-line monotherapy for ESCC in China and the combination therapy might be a promising strategy. Here we reported the update results and futhur evaluated the efficacy and safety of paclitaxel and cisplatin combined with anlotinib as first-line therapy in advanced ESCC. Methods: Pts with previously untreated metastatic or unresectable, locally advanced ESCC, who had not received (neo) adjuvant therapy/radical surgery within 6 months were recruited. Eligible patients were given paclitaxel (135mg/m2, iv, q3w) and cisplatin (60̃75mg/m2, iv, d1̃3, q3w) plus anlotinib (10mg, po, d1̃14, q3w) for 4̃6 cycles as initial therapy. Maintenance treatment was administered to those without disease progression with anlotinib monotherapy (10mg, po, d1̃14, q3w) until progression or unacceptable toxicity. The primary endpoint was PFS and secondary endpoints included safety, ORR, DCR and DOR. The predefined sample size was 47. Tumor response was assessed by investigators according to RECIST version 1.1 criteria using CT scans every two cycles. Results: From Oct 2019 to Mar 2021, a total of 47 pts with ESCC were included and 46 pts were included in intention-to treat analysis, among whom 4 CR (8.7%), 31 PR (67.4%) and 7 SD (15.2%) were observed and 4 patients (8.7%) were not available for efficacy assessment. Consequently, ORR was 76.1% (95%CI: 61.2%-87.4%) and DCR was 91.3% (95%CI: 79.2%-97.6%). At the cut-off date on July 15, 2021, 23 pts discontinued treatment due to PD, the preliminary median PFS of ITT patients was 8.38 months (95%CI: 6.44-10.32). And the median OS was not yet available. Additionally, safety profile exhibited that the common drug-related adverse events were myelosuppression, gastrointestinal reaction, fatigue, hypertension, constipation, hypokalemia. And the common grade ≥3 adverse events were myelosuppression (29.8%), gastrointestinal reaction (10.6%), hypertension (6.3%), fatigue (4.3%) and hypokalemia (4.3%). Conclusions: The update results suggested that paclitaxel and cisplatin combined with anlotinib as first-line therapy for advanced ESCC exhibited encouraging efficacy and tolerable safety profile. And the conclusion should be validated in more pts with ESCC subsequently. Clinical trial information: NCT04063683.
STING orchestrates the crosstalk between polyunsaturated fatty acid metabolism and inflammatory responses
Authors: Isabelle K. Vila, Hanane Chamma, Alizée Steer, Mathilde Saccas, Clara Taffoni, Evgenia Turtoi, Line S. Reinert, Saqib Hussain, Johanna Marines, Lei Jin, Xavier Bonnefont, Mathieu Hubert, Olivier Schwartz, Soren R. Paludan, Gaetan Van Simaeys, Gilles Doumont, Bijan Sobhian, Dimitrios Vlachakis, Andrei Turtoi, Nadine Laguette
Journal: Cell Metabolism (2022)

Concerted alteration of immune and metabolic homeostasis underlies several inflammation-related pathologies, ranging from metabolic syndrome to infectious diseases. Here, we explored the coordination of nucleic acid-dependent inflammatory responses and metabolic homeostasis. We reveal that the STING (stimulator of interferon genes) protein regulates metabolic homeostasis through inhibition of the fatty acid desaturase 2 (FADS2) rate-limiting enzyme in polyunsaturated fatty acid (PUFA) desaturation. STING ablation and agonist-mediated degradation increased FADS2-associated desaturase activity and led to accumulation of PUFA derivatives that drive thermogenesis. STING agonists directly activated FADS2-dependent desaturation, promoting metabolic alterations. PUFAs in turn inhibited STING, thereby regulating antiviral responses and contributing to resolving STING-associated inflammation. Thus, we have unveiled a negative regulatory feedback loop between STING and FADS2 that fine-tunes inflammatory responses. Our results highlight the role of metabolic alterations in human pathologies associated with aberrant STING activation and STING-targeting therapies.
New surgical techniques ease incontinence
Authors: T. Hager
Journal: JAMA (1983)

According to reports from the recent American Urological Society national meeting in Las Vegas, still-investigational methods of improving urinary sphincter function and of replacing the muscle should it fail look promising. Furthermore, there may be more to the sphincter than was previously thought. Several reports, for example, emphasized the growing value of the artificial sphincter in treating patients with spinal cord injuries as well as those requiring intermittent catheterization. The artificial sphincter consists of a silicone rubber cuff, a small pump, a balloon, and a stainless steel control assembly. When surgically implanted, the cuff is placed around the neck of the bladder (or some-times, in men, around the bulbous urethrae), the balloon is positioned in the prevesical space, and the pump is inserted under the skin either in the scrotum in males or the labia minora in women. When filled with fluid, the cuff cuts off the flow of urine
Contents
Authors: Scott Grossman, Rachel Calix, Sharon Tow, Jeffrey Odel, Linus Sun, Laura Balcer, Steven Galetta, Janet Rucker, Edmund Tsui, Rajesh Rao, Andrew Carey, Matthew Feng, Lorraine Provencher, Ryan Kidd Man, Alfred Tau, Liang Gan, Eva Fenwick, Sahil Thakur, Preeti Gupta, Ling Teo, Ching-Yu Cheng, Tien Wong, Ecosse Lamoureux, Suryan Dunker, Mor Dickman, Robert Wisse, Siamak Nobacht, Robert Wijdh, Marjolijn Bartels, Mei Tang, Frank Van Den Biggelaar, Pieter Kruit, Rudy Nuijts, Massimo Busin, Angeli Yu
Journal: Ophthalmology (2020)
Efficacy of Therapeutic Aquatic Exercise vs Physical Therapy Modalities for Patients With Chronic Low Back Pain
Authors: Meng-Si Peng, Rui Wang, Yi-Zu Wang, Chang-Cheng Chen, Juan Wang, Xiao-Chen Liu, Ge Song, Jia-Bao Guo, Pei-Jie Chen, Xue-Qiang Wang
Journal: JAMA Network Open (2022)

Therapeutic aquatic exercise is frequently offered to patients with chronic low back pain, but its long-term benefits are unclear.
Inhibition of miR-331-3p and miR-9-5p ameliorates Alzheimer's disease by enhancing autophagy: Erratum
Authors: Meng-Lu Chen, Chun-Gu Hong, Tao Yue, Hong-Ming Li, Ran Duan, Wen-Bao Hu, Jia Cao, Zhen-Xing Wang, Chun-Yuan Chen, Xiong-Ke Hu, Ben Wu, Hao-Ming Liu, Yi-Juan Tan, Jiang-Hua Liu, Zhong-Wei Luo, Yan Zhang, Shan-Shan Rao, Ming-Jie Luo, Hao Yin, Yi-Yi Wang, Kun Xia, Si-Yuan Tang, Hui Xie, Zheng-Zhao Liu
Journal: Theranostics (2021)

[This corrects the article DOI: 10.7150/thno.47408.].
Council on Industrial Health
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Citations
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 17114: CHA <sub>2</sub> DS <sub>2</sub> -VASc Score is a Poor Predictor of Thromboembolic Events in Heart Failure Patients With and Without Atrial Fibrillation
Authors: Harold Rivner, George R Marzouka, Fei Tang, Jeffrey J Goldberger
Journal: Circulation (2018)

Introduction: Recent evidence suggests that the CHA 2 DS 2 -VASc score could be used to predict thromboembolic events (TE) (both CVA and noncerebral thromboembolism) in heart failure (HF) patients without atrial fibrillation (AF). This non-American cohort study had several limitations. We performed a retrospective analysis using the national Veteran Affairs database to externally validate the findings. Hypothesis: The CHA 2 DS 2 -VASc score can be used equally to predict TE in HF patients with or without AF. Methods: A retrospective cohort of the national Veteran’s Affairs database was used to identify HF patients discharged between 2002-2010. Rates for TE were calculated at both 1 and 5 years. C-statistics were calculated to test the performance of CHA 2 DS 2 -VASc in predicting the rate of TE in HF patients with and without AF. Patients who developed AF during the follow-up period (crossovers) and those on anticoagulation where excluded. Negative predictive value was calculated using cutoff value of 1. Results: A total of 77,601 patients were included in this analysis: 51,667 without AF and 15,630 with AF. 10,294 crossover patients were excluded. Baseline characteristics and medications are listed in Table 1. Event rates are reported in Table 2—there is a small trend towards higher incidence with increasing score in both groups. However, C-statistics were overall poor but similar for predicting TE in both groups (Table 3) Conclusion: Our analysis suggests CHA 2 DS 2 -VASc is a poor predictive model for TE in HF with or without AF. We found that previous conclusions regarding the predictive ability of CHA 2 DS 2 -VASc are not generalizable to our large American cohort. Like previously published studies, we show that the predictive ability of CHA 2 DS 2 -VASc was similar in both HF patients with or without AF, despite excluding patient receiving anticoagulation. This suggests that AF may not be the main predictor of TE in HF patients. There is a need for better predictive models for TE in HF.
Recurrence after treatment of In-Stent restenosis: Does diabetes impact outcomes in large vessels? Milena G. Adamian, Roxana Mehran, Yoshio Kobayashi, George Dangas, Issam Moussa, Michael B. Collins, Lynn Glasser, Gishel New, Alexandra J. Lansky, Gregg W. Stone, Martin B. Leon, Antonio Colombo, Jeffrey W. Moses. Lenox Hill Heart and Vascular Institute, Cardiovascular Research Foundation, New York, NY, Centro Cuore Columbus, Milan, Italy
Journal: Journal of the American College of Cardiology (2001)
Withholding of Life-Sustaining Treatment From the Terminally III, Incompetent Patient: Who Decides?
Authors: Daniel G. Suber
Journal: JAMA (1982)

As a result of the prodigious technological advances of modern medicine, physicians are increasingly confronted with the question of when, and under what circumstances, life-sustaining care should be withdrawn from terminally ill patients. In the wake of recent court decisions recognizing patients' rights to refuse medical treatment, new complexities have been introduced into the process of deciding whether so-called "extraordinary measures" should be used to prolong life. Chief among these is the problem of determining who, in addition to the physician, should be involved in making such decisions. As the dilemma often arises in the context of treatment of patients who are incapacitated or mentally deficient and, thus, legally incompetent to render informed consent, the question of "who should decide" has emerged as the central issue facing the physician and the courts. Also of primary concern to physicians is the associated question of what legal consequences might follow from the
Comparison of Different Techniques to Identify Cardiac Involvement in Immunoglobulin Light Chain Amyloidosis
Authors: Mohammed A Aljama, M Hasib Sidiqi, Angela Dispenzieri, Morie A. Gertz, Martha Q. Lacy, Francis K. Buadi, David Dingli, Eli Muchtar, Amie Fonder, Suzanne R. Hayman, Miriam Hobbs, Wilson I Gonsalves, Rahma Warsame, Taxiarchis Kourelis, Lisa Hwa, Prashant Kapoor, Nelson Leung, Ronald S. Go, Robert A. Kyle, S. Vincent Rajkumar, Shaji K. Kumar
Journal: Blood (2018)